Parkinson's disease

Key cogs in the management of Parkinson’s disease
Key cogs in the management of Parkinson’s diseaseThe goal of this activity is to assist pharmacists in managing difficult-to-treat symptoms of Parkinson’s disease.
First drug approved for hallucinations in Parkinson’sFDA approved the first drug to hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease.
Diabetes drug may reduce Parkinson’s incidenceDiabetes patients taking rosiglitazone or pioglitazone had a 28 percent lower incidence of Parkinson's disease (PD) than people taking other treatments for diabetes who had never taken the glitazone (GTZ) drugs, according to a new study.
Parkinson’s disease: Unmet needs to be fulfilled by novel therapies and reformulationsThe current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.
First-in-class therapy promising for Parkinson's disease psychosisA first-in-class antipsychotic that is a selective serotonin inverse agonist (with no dopaminergic, histaminergic, adrenergic, or muscarinic activity) potentially targeting 5-HT2A receptors, improved Parkinson’s disease psychosis (PDP) with demonstrated safety and tolerability, and without worsening motor Parkinson’s, according to data presented in two posters at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS), in San Diego.
FDA approves generic Comtan tablets for Parkinson'sFDA has approved Aurobindo’s entacapone tablets USP, 200 mg, the generic equivalent to Novartis’ Comtan tablets 200 mg.
Study: Reduce long-term care use among patients with Parkinson’s disease psychosisReducing long-term care utilization among patients with Parkinson’s disease psychosis (PDP) may lower overall economic burden, according to data presented at the American Managed Care Pharmacy 27th Annual Meeting & Expo in San Diego.
People's perceptions of drug's cost may affect how much patients benefitPatients perceptions of drug cost may affect how they benefit from the drug, even when receiving a placebo.
FDA OKs carbidopa/levodopa enteral suspension for Parkinson'sFDA has approved carbidopa-levodopa (Duopa, AbbVie) enteral suspension for the treatment of patients with advanced Parkinson’s disease.
FDA approves Rytary for Parkinson’s diseaseFDA approved an extended-release oral capsule formulation of carbidopa-levodopa (Rytary, Impax Pharmaceuticals, a division of Impax Laboratories, Inc.) for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.